Germline p53 gene mutations in subsets of glioma patients

Athanassios P. Kyritsis, Melissa L. Bondy, Mi Xiao, Elise L. Berman, Joan E. Cunningham, Polly S. Lee, Victor A. Levin, Hideyuki Saya

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Background: Heritable germline mutations of the p53 gene have been described in patients with Li-Fraumeni syndrome, occasionally in nonfamilial malignancies such as multifocal osteosarcoma, in a small subgroup of young patients with two or more primary malignancies, and in patients with sporadic breast carcinoma. We recently reported that multifocal gliomas are frequently associated with other primary malignancies, and we hypothesized that genetic alterations may account for this phenomenon. Purpose: We examined the frequency of germline p53 gene mutations in patients with glioma and either multifocality of lesions, history of an additional primary (different) malignancy, or a family history of cancer. Methods: Lymphocytes from 51 glioma patients were analyzed for germline p53 gene mutations using RNA- polymerase chain reaction analysis, single-strand conformation polymorphism, and gene sequencing techniques. Results: Germline p53 gene mutations were detected in six of 19 patients with multifocal glioma, including two with family history of cancer, one with another primary malignancy, and two with all three risk factors; one of four patients with unifocal glioma, another primary malignancy, and a family history of cancer; and two of 15 patients with unifocal glioma and a family history of cancer but no second malignancies. No mutations were detected in the patient with unifocal glioma and another malignancy or in the 12 control patients with unifocal glioma and no second malignancies or family history of cancer. Patients having mutations were younger than other patients in the same group. Conclusions: Germline p53 mutations are frequent in patients with multifocal glioma, glioma and another primary malignancy, and glioma associated with a family history of cancer, particularly if these factors are combined. Implications: Relatives at high risk can be identified for genetic counseling, early cancer detection, and possible enrollment in chemoprevention trials.

Original languageEnglish
Pages (from-to)344-349
Number of pages6
JournalJournal of the National Cancer Institute
Volume86
Issue number5
Publication statusPublished - 1994 Mar 2
Externally publishedYes

Fingerprint

p53 Genes
Glioma
Cancer
Mutation
Genes
Gene
Subset
Neoplasms
Lymphocytes
Polymerase chain reaction
Polymorphism
RNA
Conformations
Polymerase Chain Reaction
Second Primary Neoplasms
Germ-Line Mutation
Risk Factors
History
Conformation
Sequencing

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Kyritsis, A. P., Bondy, M. L., Xiao, M., Berman, E. L., Cunningham, J. E., Lee, P. S., ... Saya, H. (1994). Germline p53 gene mutations in subsets of glioma patients. Journal of the National Cancer Institute, 86(5), 344-349.

Germline p53 gene mutations in subsets of glioma patients. / Kyritsis, Athanassios P.; Bondy, Melissa L.; Xiao, Mi; Berman, Elise L.; Cunningham, Joan E.; Lee, Polly S.; Levin, Victor A.; Saya, Hideyuki.

In: Journal of the National Cancer Institute, Vol. 86, No. 5, 02.03.1994, p. 344-349.

Research output: Contribution to journalArticle

Kyritsis, AP, Bondy, ML, Xiao, M, Berman, EL, Cunningham, JE, Lee, PS, Levin, VA & Saya, H 1994, 'Germline p53 gene mutations in subsets of glioma patients', Journal of the National Cancer Institute, vol. 86, no. 5, pp. 344-349.
Kyritsis AP, Bondy ML, Xiao M, Berman EL, Cunningham JE, Lee PS et al. Germline p53 gene mutations in subsets of glioma patients. Journal of the National Cancer Institute. 1994 Mar 2;86(5):344-349.
Kyritsis, Athanassios P. ; Bondy, Melissa L. ; Xiao, Mi ; Berman, Elise L. ; Cunningham, Joan E. ; Lee, Polly S. ; Levin, Victor A. ; Saya, Hideyuki. / Germline p53 gene mutations in subsets of glioma patients. In: Journal of the National Cancer Institute. 1994 ; Vol. 86, No. 5. pp. 344-349.
@article{5e29e2a341594c8e89dec399dc26ccab,
title = "Germline p53 gene mutations in subsets of glioma patients",
abstract = "Background: Heritable germline mutations of the p53 gene have been described in patients with Li-Fraumeni syndrome, occasionally in nonfamilial malignancies such as multifocal osteosarcoma, in a small subgroup of young patients with two or more primary malignancies, and in patients with sporadic breast carcinoma. We recently reported that multifocal gliomas are frequently associated with other primary malignancies, and we hypothesized that genetic alterations may account for this phenomenon. Purpose: We examined the frequency of germline p53 gene mutations in patients with glioma and either multifocality of lesions, history of an additional primary (different) malignancy, or a family history of cancer. Methods: Lymphocytes from 51 glioma patients were analyzed for germline p53 gene mutations using RNA- polymerase chain reaction analysis, single-strand conformation polymorphism, and gene sequencing techniques. Results: Germline p53 gene mutations were detected in six of 19 patients with multifocal glioma, including two with family history of cancer, one with another primary malignancy, and two with all three risk factors; one of four patients with unifocal glioma, another primary malignancy, and a family history of cancer; and two of 15 patients with unifocal glioma and a family history of cancer but no second malignancies. No mutations were detected in the patient with unifocal glioma and another malignancy or in the 12 control patients with unifocal glioma and no second malignancies or family history of cancer. Patients having mutations were younger than other patients in the same group. Conclusions: Germline p53 mutations are frequent in patients with multifocal glioma, glioma and another primary malignancy, and glioma associated with a family history of cancer, particularly if these factors are combined. Implications: Relatives at high risk can be identified for genetic counseling, early cancer detection, and possible enrollment in chemoprevention trials.",
author = "Kyritsis, {Athanassios P.} and Bondy, {Melissa L.} and Mi Xiao and Berman, {Elise L.} and Cunningham, {Joan E.} and Lee, {Polly S.} and Levin, {Victor A.} and Hideyuki Saya",
year = "1994",
month = "3",
day = "2",
language = "English",
volume = "86",
pages = "344--349",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Germline p53 gene mutations in subsets of glioma patients

AU - Kyritsis, Athanassios P.

AU - Bondy, Melissa L.

AU - Xiao, Mi

AU - Berman, Elise L.

AU - Cunningham, Joan E.

AU - Lee, Polly S.

AU - Levin, Victor A.

AU - Saya, Hideyuki

PY - 1994/3/2

Y1 - 1994/3/2

N2 - Background: Heritable germline mutations of the p53 gene have been described in patients with Li-Fraumeni syndrome, occasionally in nonfamilial malignancies such as multifocal osteosarcoma, in a small subgroup of young patients with two or more primary malignancies, and in patients with sporadic breast carcinoma. We recently reported that multifocal gliomas are frequently associated with other primary malignancies, and we hypothesized that genetic alterations may account for this phenomenon. Purpose: We examined the frequency of germline p53 gene mutations in patients with glioma and either multifocality of lesions, history of an additional primary (different) malignancy, or a family history of cancer. Methods: Lymphocytes from 51 glioma patients were analyzed for germline p53 gene mutations using RNA- polymerase chain reaction analysis, single-strand conformation polymorphism, and gene sequencing techniques. Results: Germline p53 gene mutations were detected in six of 19 patients with multifocal glioma, including two with family history of cancer, one with another primary malignancy, and two with all three risk factors; one of four patients with unifocal glioma, another primary malignancy, and a family history of cancer; and two of 15 patients with unifocal glioma and a family history of cancer but no second malignancies. No mutations were detected in the patient with unifocal glioma and another malignancy or in the 12 control patients with unifocal glioma and no second malignancies or family history of cancer. Patients having mutations were younger than other patients in the same group. Conclusions: Germline p53 mutations are frequent in patients with multifocal glioma, glioma and another primary malignancy, and glioma associated with a family history of cancer, particularly if these factors are combined. Implications: Relatives at high risk can be identified for genetic counseling, early cancer detection, and possible enrollment in chemoprevention trials.

AB - Background: Heritable germline mutations of the p53 gene have been described in patients with Li-Fraumeni syndrome, occasionally in nonfamilial malignancies such as multifocal osteosarcoma, in a small subgroup of young patients with two or more primary malignancies, and in patients with sporadic breast carcinoma. We recently reported that multifocal gliomas are frequently associated with other primary malignancies, and we hypothesized that genetic alterations may account for this phenomenon. Purpose: We examined the frequency of germline p53 gene mutations in patients with glioma and either multifocality of lesions, history of an additional primary (different) malignancy, or a family history of cancer. Methods: Lymphocytes from 51 glioma patients were analyzed for germline p53 gene mutations using RNA- polymerase chain reaction analysis, single-strand conformation polymorphism, and gene sequencing techniques. Results: Germline p53 gene mutations were detected in six of 19 patients with multifocal glioma, including two with family history of cancer, one with another primary malignancy, and two with all three risk factors; one of four patients with unifocal glioma, another primary malignancy, and a family history of cancer; and two of 15 patients with unifocal glioma and a family history of cancer but no second malignancies. No mutations were detected in the patient with unifocal glioma and another malignancy or in the 12 control patients with unifocal glioma and no second malignancies or family history of cancer. Patients having mutations were younger than other patients in the same group. Conclusions: Germline p53 mutations are frequent in patients with multifocal glioma, glioma and another primary malignancy, and glioma associated with a family history of cancer, particularly if these factors are combined. Implications: Relatives at high risk can be identified for genetic counseling, early cancer detection, and possible enrollment in chemoprevention trials.

UR - http://www.scopus.com/inward/record.url?scp=0028221553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028221553&partnerID=8YFLogxK

M3 - Article

C2 - 8308926

AN - SCOPUS:0028221553

VL - 86

SP - 344

EP - 349

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

ER -